The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a pr
The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a preparation of hydrophilic cellular components and a preparation of hydrophobic cellular components. In some embodiments, the preparation of hydrophilic cellular components is encapsulated within the internal lumen and the preparation of hydrophobic cellular components is associated with the external surface. Various methods of making and using disclosed nanoparticle compositions are also provided.
대표청구항▼
1. A nanoparticle composition comprising: a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure whose external surface is coated with a preparation comprising a crude hydrophobic bacterial extract and a hydrophilic a
1. A nanoparticle composition comprising: a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure whose external surface is coated with a preparation comprising a crude hydrophobic bacterial extract and a hydrophilic antigen encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components. 2. The nanoparticle composition of claim 1, wherein the nanoparticles each also comprise a preparation comprising one or more hydrophilic cellular components. 3. The nanoparticle composition of claim 1, wherein the nanoparticles each further comprise a second antigen, optionally also encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components. 4. The nanoparticle composition of claim 1, wherein the antigen is selected from the group consisting of an allergic antigen, an anaphylactic antigen, an infectious antigen, an autoantigen, a disease-associated antigen, a food antigen, a microbial antigen, a viral antigen, a tumor antigen, and an environmental antigen. 5. The nanoparticle composition of claim 1, wherein the biodegradable or biocompatible polymer is poly(lactic-co-glycolic acid). 6. A method comprising administering to a human subject in need thereof a nanoparticle composition comprising: a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure whose external surface is coated with a preparation comprising a crude hydrophobic bacterial extract; anda hydrophilic antigen encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to the human subject, the antigen is hidden from immune system components. 7. The method of claim 6, wherein the antigen is selected from the group consisting of an allergic antigen, an anaphylactic antigen, an infectious antigen, an autoantigen, a disease-associated antigen, a food antigen, a microbial antigen, a viral antigen, a tumor antigen, and an environmental antigen. 8. The method of claim 6, wherein the nanoparticles each further comprise a second antigen, optionally also encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components. 9. The method of claim 6, wherein the subject is suffering from at least one of allergy, infection, and cancer. 10. The method of claim 6, wherein the nanoparticle is administered intravenously, intradermally, transdermally, orally, subcutaneously, and/or transmucosally. 11. A method of forming a nanoparticle composition comprising: providing a hydrophilic preparation comprising an antigen;providing a biodegradable or biocompatible polymer;associating the hydrophilic preparation with the biodegradable or biocompatible polymer so that nanoparticles comprising the polymer and the preparation are formed; andcoating the nanoparticles with a crude hydrophobic bacterial extract. 12. The method of claim 11, wherein the nanoparticle composition further comprises an antigen. 13. The method of claim 12, wherein the antigen is selected from the group consisting of an allergic antigen, an anaphylactic antigen, an infectious antigen, an autoantigen, a disease-associated antigen, a food antigen, a microbial antigen, a viral antigen, a tumor antigen, and an environmental antigen. 14. The method of claim 12, wherein the nanoparticles each further comprise a second antigen, optionally also encapsulated by the nanoparticle structure so that, when the nanoparticle composition is administered to a subject, the antigen is hidden from immune system components. 15. The composition of claim 2, wherein the crude hydrophobic bacterial extract of a cellular preparation further comprises immunological components present in absolute or relative amounts as compared to those found in natural microbial cells. 16. The composition of claim 2 or 4, wherein the antigen is provided as a crude hydrophilic extract of a biological source. 17. The composition of claim 2, wherein the preparation comprises a crude hydrophilic cellular extract. 18. The composition of claim 17, wherein the crude hydrophilic cellular extract comprises or consists of an aqueous cellular extract. 19. The composition of claim 18, wherein the cellular extract is a microbial extract. 20. The composition of claim 3, wherein the second antigen is optionally an allergic antigen, an anaphylactic antigen, an infection antigen, an autoantigen, or a disease-associated antigen.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (99)
Eberle Marcel K. (Riehen CHX), 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8cyclosporins.
Sinclair Peter J. (Highland Park NJ) Organ Helen M. (Roselle Park NJ) Wyvratt Matthew J. (Mountainside NJ), Amino O-aryl macrolides having immunosuppressive activity.
Ok Hyun O. (Edison NJ) Beattie Thomas R. (Scotch Plains NJ) Fisher Michael H. (Ringoes NJ) Wyvratt Matthew J. (Mountainside NJ) Goulet Mark (Westfield NJ), Aminomacrolides and derivatives having immunosuppressive activity.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Goulet Mark (Westfield NJ) Beattie Thomas R. (Scotch Plains NJ) Wyvratt Matthew J. (Mountainside NJ), Fluoromacrolides having immunosuppressive activity.
Patchett Arthur A. (Westfield NJ) Taub David (Metuchen NJ) Goegelman Robert T. (Linden NJ), Immunosuppressive cyclosporin analogs with modified amino acids at position-8.
Durette Philippe L. (New Providence NJ) Pessolano Arsenio A. (Colonia NJ) Kollonitsch Janos (Westfield NJ), Immunosuppressive fluorinated cyclosporin analogs.
Mohr Judy M. (Menlo Park CA) Baker Richard W. (Palo Alto CA) Nakaji Lisa A. (San Jose CA), Liquid reservoir transdermal patch for the administration of ketorolac.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Ok Hyun O. (Edison NJ) Goulet Joung (Westfield NJ) Sinclair Peter J. (Highland Park NJ), N-heteroaryl, N-alkylheteroaryl, N-alkenylheteroaryl and N-alkynylheteroarylmacrolides having immunosuppressive activity.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Burks, Jr.,A. Wesley; Bannon,Gary A.; Sampson,Hugh A.; Helm,Ricki M.; Stanley,J. Steven; Rabjohn,Patrick A., Nucleic acids encoding ara h 3 polypeptides.
Goulet Mark (Westfield NJ) Organ Helen M. (Fanwood NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity.
Goulet Mark (Westfield NJ) Wong Frederick (Glen Ridge NJ) Sinclair Peter J. (Highland Park NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives.
Goulet Mark (Westfield NJ) Parsons William H. (Edison NJ) Organ Helen M. (Fanwood NJ) Sinclair Peter J. (Highland Park NJ) Wong Frederick (Glen Ridge NJ) Wyvratt Matthew J. (Mountainside NJ), O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity.
A. Wesley Burks, Jr. ; J. Steven Stanley ; Gael Cockrell ; Nina E. King ; Hugh A. Sampson ; Ricki M. Helm ; Gary A. Bannon, Peanut allergens and methods.
Okuhara Masakuni (Ibaraki JPX) Tanaka Hirokazu (Ibaraki JPX) Goto Toshio (Ibaraki JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Ibaraki JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
Okuhara Masakuni (Ibaraki JPX) Tanaka Hirokazu (Ibaraki JPX) Goto Toshio (Ibaraki JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Ibaraki JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
Okuhara Masakuni (Sakuramura JPX) Tanaka Hirokazu (Sakuramura JPX) Goto Toshio (Sakuramura JPX) Kino Tohru (Tsuchiura JPX) Hatanaka Hiroshi (Sakuramura JPX), Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.